EV is named as a drug or biological intervention in 2 clinical trials in our UK, USA and China trial registers, 2 of which are recruiting. Lead sponsors include Merck Sharp & Dohme LLC (1) and Eli Lilly and Company (1). Registered phases: Phase 1/2 and Phase 3. Conditions studied include Bladder Cancer; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07218380 | A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract (ClinicalTrials.gov ↗) Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis |
Phase 3 | Recruiting |
| NCT07232602 | KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) (ClinicalTrials.gov ↗) Bladder Cancer |
Phase 1/2 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Bladder Cancer | 1 |
| Carcinoma, Transitional Cell | 1 |
| Urinary Bladder Neoplasms | 1 |
| Neoplasm Metastasis | 1 |
| Lead sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 1 |
| Eli Lilly and Company | 1 |
| Register | EV trials |
|---|---|
| Clinical trials in UK | 2 |
| Clinical trials in USA | 2 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how EV works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists EV (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.